课题基金 / 基金详情

Correction of the DMD gene with the CRISPR/Cas9 technology: restoring the reading frame and production of a dystrophin protein with an adequate structure.

Correction of the DMD gene with the CRISPR/Cas9 technology: restoring the reading frame and production of a dystrophin protein with an adequate structure.
利用CRISPR/Cas9技术校正DMD基因:恢复阅读框并产生具有适当结构的肌营养不良蛋白。
批准号:
366623
负责人:
Tremblay Jacques P
金额:
$7.29万
依托单位:
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2016
资助国家:
加拿大
项目状态:
已结题
起止时间:
2016-11-01 至 2017-11-01

项目摘要

项目成果

Tremblay Jacques P的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The long-term aim of the project is to develop a therapy for Duchenne Muscular Dystrophy (DMD) patients having any point mutation, duplication or exon deletion in the dystrophin gene between exons 48 and 57. This will be done by correcting the dystrophin
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Correction with the Prime editing technology of point mutations responsible for Duchenne Muscular Dystrophy.
  • 批准号:
    472649
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2022
  • 负责人:
    Tremblay Jacques P
  • 依托单位:
Development of a rapid and simple test to detect the COVID-19 variants that can be used in remote areas and developing countries.
  • 批准号:
    448988
  • 项目类别:
    Operating Grants
  • 资助金额:
    $14.51万
  • 财政年份:
    2021
  • 负责人:
    Tremblay Jacques P
  • 依托单位:
Removal of the GAA repeat with the CRISPR/Cas9 system in Friedreich patient cells and in the YG8sR mouse model."
  • 批准号:
    400052
  • 项目类别:
    Operating Grants
  • 资助金额:
    $54.89万
  • 财政年份:
    2019
  • 负责人:
    Tremblay Jacques P
  • 依托单位:
Alzheimer treatment based on the editing of the Amyloid Precursor Protein gene
  • 批准号:
    325047
  • 项目类别:
    Operating Grants
  • 资助金额:
    $11.65万
  • 财政年份:
    2015
  • 负责人:
    Tremblay Jacques P
  • 依托单位:
海外基金